Table 3.
Effect of sodium bicarbonate on bone biomarkers
| Variable | Treatment | % Mean Change (95% CI) | P Value for % Mean Change Compared with Placebo | P Value Adjusted for Multiple Comparison |
|---|---|---|---|---|
| iFGF-23 | Placebo | 6.5 (0.9 to 12.1) | — | |
| Lower dose | 8.1 (2.5 to 13.7) | 0.697 | 0.867 | |
| Higher dose | 1.7 (−2.8 to 6.3) | 0.193 | 0.603 | |
| Both doses | 4.3 (0.8 to 7.8) | 0.511 | 0.712 | |
| iPTH | Placebo | −0.5 (−7.2 to 6.3) | — | |
| Lower dose | 9.6 (3.0 to 16.4) | 0.036 | 0.270 | |
| Higher dose | 4.1 (−1.3 to 9.4) | 0.301 | 0.658 | |
| Both doses | 6.3 (2.1 to 10.4) | 0.096 | 0.576 | |
| Soluble klotho | Placebo | −3.3 (−5.8 to −0.9) | — | |
| Lower dose | 0.7 (−1.7 to 3.2) | 0.023 | 0.230 | |
| Higher dose | 2.7 (0.7 to 4.7) | <0.001 | 0.006 | |
| Both doses | 1.9 (0.3 to 3.5) | <0.001 | 0.008 | |
| 25(OH) vitamin D | Placebo | 0.2 (−3.3 to 3.8) | — | |
| Lower dose | 2.5 (−1.0 to 6.0) | 0.376 | 0.705 | |
| Higher dose | 0.2 (−2.7 to 3.0) | 0.981 | 0.993 | |
| Both doses | 1.1 (−1.1 to 3.3) | 0.685 | 0.867 | |
| 1,25(OH)2 vitamin D | Placebo | −2.0 (−6.5 to 2.5) | — | |
| Lower dose | 1.7 (−2.7 to 6.1) | 0.247 | 0.658 | |
| Higher dose | 1.3 (−2.3 to 4.9) | 0.264 | 0.658 | |
| Both doses | 1.4 (−1.3 to 4.2) | 0.201 | 0.603 | |
| Urine calcium/Cr | Placebo | 7.3 (−8.3 to 22.8) | — | |
| Lower dose | −1.7 (−17.2 to 13.7) | 0.421 | 0.707 | |
| Higher dose | 0.8 (−11.5 to 13.1) | 0.522 | 0.712 | |
| Both doses | −0.2 (−9.8 to 9.4) | 0.424 | 0.707 | |
| B-SAP | Placebo | 0.1 (−2.2 to 2.5) | — | |
| Lower dose | −2.1 (−4.4 to 0.2) | 0.184 | 0.603 | |
| Higher dose | −1.4 (−3.3 to 0.4) | 0.310 | 0.658 | |
| Both doses | −1.7 (−3.1 to −0.3) | 0.197 | 0.603 | |
| CTX-1 | Placebo | 0.06 (−7.2 to 7.3) | — | |
| Lower dose | 7.1 (−0.2 to 14.4) | 0.183 | 0.603 | |
| Higher dose | −4.6 (−10.6 to 1.3) | 0.329 | 0.658 | |
| Both doses | 0 (−4.6 to 4.7) | 0.993 | 0.993 | |
| P1NP | Placebo | −1.1 (−5.2 to 2.9) | — | |
| Lower dose | −3.0 (−7.0 to 0.1) | 0.516 | 0.712 | |
| Higher dose | 0.8 (−2.5 to 4.1) | 0.461 | 0.712 | |
| Both doses | −0.7 (−3.3 to 1.8) | 0.870 | 0.932 | |
| TRAP5b | Placebo | 0.3 (−7.5 to 8.0) | — | |
| Lower dose | −1.5 (−9.2 to 6.2) | 0.752 | 0.867 | |
| Higher dose | −1.1 (−7.4 to 5.1) | 0.780 | 0.867 | |
| Both doses | −1.3 (−6.1 to 3.5) | 0.738 | 0.867 |
B-SAP, bone-specific alkaline phosphatase; CI, confidence interval; Cr, creatinine; CTX-1, C-terminal telopeptide of type I collagen; iFGF23, intact fibroblast growth factor-23; OH, hydroxy; P1NP, procollagen type I intact N-terminal propeptide; iPTH, intact parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase 5b.